Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 14.3% Following Earnings Beat

Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) rose 14.3% on Thursday following a stronger than expected earnings report. The stock traded as high as $14.18 and last traded at $14.0770. Approximately 288,155 shares traded hands during mid-day trading, a decline of 75% from the average daily volume of 1,147,177 shares. The stock had previously closed at $12.32.

The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. The business had revenue of $57.58 million for the quarter, compared to analysts’ expectations of $57.44 million.

Key Headlines Impacting Phathom Pharmaceuticals

Here are the key news stories impacting Phathom Pharmaceuticals this week:

• Positive Sentiment: Guggenheim raised its price target to $25 and upgraded PHAT to a “buy”, implying large upside from current levels — a clear analyst endorsement that can support the stock over the medium term. Guggenheim PT Raise (Benzinga)
• Positive Sentiment: Management issued FY‑2026 revenue guidance of $320M–$345M and reiterated a target of operating profitability beginning in Q3 2026 and for the full year — guidance above street revenue consensus and a near‑term path to profitability are constructive for valuation. 2026 Guidance (Seeking Alpha)
• Positive Sentiment: Q4 results beat: EPS of ($0.08) vs. consensus ($0.09) and revenue $57.6M vs. $57.4M; FY2025 revenue jumped to $175.1M (≈217% YoY) and VOQUEZNA® prescriptions topped 1.1M — evidence of strong commercial traction. Q4 Results & Press Release (GlobeNewswire)
• Neutral Sentiment: Company says it strengthened its balance sheet via a $130M equity offering and a term‑debt modification; management reported modest net cash usage — this improves runway but the equity raise can be dilutive, which may temper upside. Balance Sheet Update (GlobeNewswire)
• Neutral Sentiment: Earnings materials (presentation and call transcript) are available for review — useful for details on sales cadence, launch math and timing to profitability but not new headlines by themselves. Earnings Presentation (Seeking Alpha) Earnings Transcript (Seeking Alpha)
• Neutral Sentiment: Preview and analyst commentary published around the Q4 print are available for reading; they summarize expectations and may influence near‑term sentiment but contain no fresh operational surprises. Q4 Preview (Yahoo Finance)

Wall Street Analyst Weigh In

PHAT has been the subject of a number of analyst reports. Stifel Nicolaus set a $28.00 price target on Phathom Pharmaceuticals in a report on Thursday. HC Wainwright upped their target price on Phathom Pharmaceuticals from $20.00 to $26.00 and gave the company a “buy” rating in a report on Friday, October 31st. Guggenheim lifted their price target on Phathom Pharmaceuticals from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Friday. Raymond James Financial began coverage on shares of Phathom Pharmaceuticals in a report on Thursday, December 11th. They issued a “strong-buy” rating and a $28.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $22.25.

Institutional Trading of Phathom Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. boosted its position in shares of Phathom Pharmaceuticals by 23.3% during the second quarter. Frazier Life Sciences Management L.P. now owns 12,466,489 shares of the company’s stock worth $119,554,000 after buying an additional 2,357,210 shares during the period. Millennium Management LLC grew its position in Phathom Pharmaceuticals by 125.8% in the 3rd quarter. Millennium Management LLC now owns 5,081,451 shares of the company’s stock valued at $59,809,000 after acquiring an additional 2,830,954 shares in the last quarter. Invesco Ltd. grew its position in Phathom Pharmaceuticals by 13.4% in the 2nd quarter. Invesco Ltd. now owns 4,140,072 shares of the company’s stock valued at $39,703,000 after acquiring an additional 489,260 shares in the last quarter. Vanguard Group Inc. increased its stake in Phathom Pharmaceuticals by 15.4% during the third quarter. Vanguard Group Inc. now owns 3,215,572 shares of the company’s stock worth $37,847,000 after purchasing an additional 428,261 shares during the period. Finally, 683 Capital Management LLC lifted its position in shares of Phathom Pharmaceuticals by 45.7% during the second quarter. 683 Capital Management LLC now owns 2,105,000 shares of the company’s stock worth $20,187,000 after purchasing an additional 660,000 shares in the last quarter. Hedge funds and other institutional investors own 99.01% of the company’s stock.

Phathom Pharmaceuticals Price Performance

The company’s 50 day moving average price is $14.30 and its 200 day moving average price is $13.47. The firm has a market cap of $897.04 million, a PE ratio of -4.10 and a beta of 0.51.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.